Cardiac dysfunction (from a heart attack) was reversed in this pre-clinical heart failure model in the pig by restoring S100A1 levels in practically the same setting as in a patient is remarkable and will pave the way for a clinical trial.
About six million people in the United States have heart failure, and it results in about 300,000 deaths each year.
The therapeutic profile of S100A1 is a unique one as it targets and reverses the underlying causes of heart failure: progressive deterioration of contractile performance, electrical instability and energy deprivation
If you liked this article, please give it a quick review on ycombinator or StumbleUpon. Thanks